Nintedanib derivative as well as preparation method and application thereof
By modifying the structure of nintedanib, a long-acting nintedanib derivative was prepared, which solved the problems of low bioavailability and large adverse reactions of nintedanib, and achieved long-acting injection administration, thus improving the therapeutic effect and patient compliance.
Patent Information
- Application Number
- CN202610088125.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-22
- Publication Date
- 2026-04-28
- Estimated Expiration
- 2046-01-22
AI Technical Summary
Existing nintedanib drugs suffer from low bioavailability and significant adverse reactions, leading to poor patient tolerance. Clinical treatment doses cannot reach the daily doses used in studies, and there is a lack of long-acting injectable administration routes to improve compliance and treatment efficacy.
By modifying the structure of nintedanib, a long-acting nintedanib derivative was prepared, forming a formulation that can be injected intramuscularly, subcutaneously, or intravenously. The drug forms a reservoir in the body and is slowly released to achieve a long-acting effect.
It improves the bioavailability of nintedanib, reduces toxicity, increases patient compliance, and maintains therapeutic levels in vivo for a long time, making it suitable for the treatment of diseases such as systemic sclerosis-related interstitial lung disease and idiopathic pulmonary fibrosis.